The global growing number of contrast-enhanced procedures highlights the risk of contrast media-induced renal damage. This review is an effort to define contrast-induced nephropathy and its pathogenesis, weigh its principal risk factors, give some clarifications about kidney function evaluation tools, acquire some clinical relevance prognostic concerns, and bring into focus preventive measures, with special regard to cancer patients. Our final purpose is focused on the request of diagnostic safety in high-risk patients, which may be achieved without unfair differences in this subgroup, too. A second reading of the scientific evidence may offer a chance to tear down the kidney damage ghost, replacing it with the consciousness of a still existing challenge that engages more than one specialty.
Introduction
The number of contrast-enhanced diagnostic examinations is exponentially growing up to millions every year all over the world. 1 Nephrologists are increasingly consulted to assess the safety of radiologic procedures in patients affected by kidney disease due to a wide literature that is still debating whether chronic and/or acute renal insufficiency should be considered as major risk factors for contrast-associated renal damage. Cancer patients represent a population at risk for kidney complications because of their higher prevalence of chronic kidney disease (CKD) with respect to the general population 2 and are exposed to chemotherapeutic agents, either cytotoxic and targeted agents or immune checkpoint inhibitors, which may cause acute renal injury, sometimes irreversible. 3 Moreover, cancer patients are highly exposed to iodinated contrast media (CM) in order to perform periodical radiological disease staging or as laid down by clinical trials protocols.
A series of questions arises from these considerations. First, what is "contrast-induced nephropathy"? Is it a mere rise of serum creatinine with no or mild clinical implication or an acute kidney injury (AKI) leading to potentially serious consequences? Second, which is the best marker of renal damage and which acute renal injury classification system shows the highest levels of predictability of the outcome? Third, which is the level of evidence that supports the augmented risk of iodinated contrast renal damage in CKD as well as in cancer patients? After clarifying these issues, we will focus on prophylactic measures to prevent kidney damage and their effectiveness.
Contrast medium and the kidney: from an etiological to an associative relationship
The first reports on the association between the administration of iodinated Contrast Medium (CM) and the development of AKI date back to the mid-1950s. 4 The acronym CIN (Contrast-Induced Nephropathy) appears at the beginning of the 1970s. 5 In those years, high-dosage (up to 70 g of iodine) hyperosmolar contrast media (HOCM) were used, and the presence of dehydration, preexisting CKD, diabetic nephropathy, anaphylactic shock due to the CM itself, or a hypovolemic status secondary to a heart disease were already identified as the main risk factors for CIN. 6 At present, HOCM, such as iothalamate and diatrizoate, are no longer used, because the high osmolality gradient between these ionic monomeric CM (1000-2500 mosm/ Kg H 2 O) and plasma (290 mosm/kg H 2 O) is considered to be responsible for kidney damage, 7, 8 developing from an oxidative and osmotic proximal tubular injury, enhanced by volume depletion that follows osmotic diuresis caused by contrast medium filtration, a picture known as "osmotic nephropathy." In the 1980s, low osmolality media contrasts (LOCM: two to three times plasma osmolality) were developed and commercialized. The meta-analysis of Barrett and Carlisle 9 published in 1993 showed the lower incidence of AKI with LOCM, particularly in patients with preexisting renal failure, and this led as a consequence to discontinue the use of HOCM in favor of LOCM.
The last step was the introduction of iso-osmolar contrast media (IOCM), developed in the 1990s in an attempt to erase the media contrast nephrotoxicity, through an osmolality of about 290 mosm/kg H 2 O. In the subsequent flowering of Randomized Controlled Trials (RCT) comparing IOCM and LOCM, another actor appeared in the pathogenesis of CIN, the viscosity. In short, to provide an imaging adequate power, radiologists have to administer a certain amount of iodine atoms. A lower osmolality was obtained through molecules capable of linking more iodine (from 1.5:1 to 6:1 ratio), reducing as a consequence the molecular number, but at the price of a greater molecular size that increases solution viscosity.
In the late 2000s, the nosological entity called "CIAKI" (contrast-induced acute kidney injury) appeared in literature. 10 The efforts made to explain the pathogenesis of kidney damage were focused on the connection between renal vasoconstriction, especially in the renal medulla, nitric oxide decrease, and hypoxic injury, where high viscosity of IOCM might have a role. The perfusion with IOCM of human descending vasa recta causes an enhanced angiotensin II response and endothelial apoptosis, as rigorously shown by Sendensky et al. 11 Outer and inner renal medulla present a unique vessel and nephronic system made of juxtamidollar nephrons (long-loop nephrons), ascending and descending vasa recta, peritubular capillaries, and interstitium, which is characterized by a progressive extracellular tonicity increase, ranging from 300 mosm/Kg H 2 O near the renal cortex to 1200 mosm/Kg H 2 O in the inner medulla in dehydration conditions. In such a picture, a direct osmotic injury is highly unlikely. If diuresis is balanced by adequate intravascular filling, and the activation of ReninAngiotensin-Aldosterone System (RAAS) prevented, the osmolar toxicity of CM should be limited or even avoided. The beneficial effect of iso-osmolar media is partially blunted by its high viscosity that may decelerate urine output and increases hydrostatic pressure in tubular lumen, lowering the net driving force in glomerular filtration resulting in glomerular filtration rate (GFR) decrease and enhancing interstitial water reabsorption resulting in an increase of interstitial pressure and hypoxic damage. 4, 12 These studies highlight the continuum between functional alteration and organic injury. The former is potentially reversible, the latter is more dangerous in terms of prognosis. Undoubtedly, reactive oxygen species (ROS) play a role in renal injury; Medullary Thick Ascending Limb (mTAL) are rich in mitochondria, the principal site of ROS generation that may be enhanced in an ischemia-reperfusion-injury picture like the one caused by CM. However, at present, the exact role of ROS in CIAKI still needs some clarifications. 13 This new knowledge on the pathogenetic mechanisms of CM renal damage explains the important role of volume depletion as a risk factor for CIAKI. In the presence of a sustained diuresis favored by a normal intravascular repletion, neither osmolarity nor viscosity seem to be able to cause per se a non-reversible renal damage. The loss of functioning nephrons, and the unbalance between vasoconstrictor and vasodilation factors in favor of the former, particularly in the elderly, the diabetics, and in those with nephroangiosclerosis, may account for the augmented risk of CIAKI in CKD compared to patients with normal renal function.
Recently, the acronym CIAKI was flanked by the more conservative CA-AKI (contrast-associated acute kidney injury). 14 This change in labeling reflects a review of scientific evidence about the etiologic link between CM and kidney damage. The marked disparity between CIAKI prevalence in different populations (inpatient vs outpatient, emergency vs elective/diagnostic procedures) suggests that other factors, besides CM toxicity, may explain renal function deterioration.
Creatinine: still the best marker of CIAKI?
In 2008, Newhouse et al. 15 published a provocative retrospective study that may lead us to the core question concerning the best marker of CIAKI. Computed Tomography (CT) without CM was performed in a group of inpatients selected by the availability of five consecutive daily creatinine measurements. These patients were considered as a control group and compared to those of several previous publications investigating the prevalence of increased creatinine levels after exposition to CM. More than 31,000 patients showing multiple risk factors for short-term creatinine changes (nephrotoxic drugs, surgery, sepsis, heart failure, glomerulonephritis, obstruction, etc.) were analyzed. Baseline serum creatinine level was 1.65 ± 2.21 mg/dL and 1.45 ± 1.78 mg/dL at day 4. More than half of patients showed a variation ≥25% (both as increase or decrease), and 15% showed a serum creatinine increase of ≥0.6 mg/ dL. Given the current biochemical definition of CIAKI (an absolute increase of serum creatinine ≥0.5 mg/dL or ≥25% of baseline at 24-72 h after contrast medium administration), the prevalence of AKI in this cohort suggests that it is likely an overdiagnosis of CIAKI in inpatients, mainly due to a scotoma in the definition of CIAKI: "AKI in absence of another known etiologies." The authors compared the prevalence of AKI to that reported in 37 previous studies using CM. Only three studies with cohorts mainly composed by diabetics and patients with moderate-severe CKD showed a greater prevalence of AKI compared to "the control group." 15 When serum creatinine increases after a radiological procedure, these findings suggest that a differential diagnosis on AKI etiology should be made before declaring that kidney damage is due to CM.
Newhouse et al. 15 point out another interesting concept regarding the clinical interpretation of serum creatinine changes. As there is an inverse exponential relationship between serum creatinine and GFR (Figure 1 ), when GFR is mildly reduced, small changes in serum creatinine levels match with great reductions in GFR, whereas in advanced renal failure, greater increases of serum creatinine may be seen with less decreases in GFR. Therefore, do we have to abandon serum creatinine? As all markers, it should be interpreted appropriately. Nephrologist's guidelines in the last 20 years have lightened up the diagnostic and prognostic value of creatinine-based formulas, such as Modification of Diet in Renal Disease Study equation (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for the evaluation of GFR in stable CKD patients. 16 The aforesaid formulas become inaccurate in a clinical setting characterized by rapid extracellular volume variations and muscle mass changes, such as in unstable patients with AKI. Anyway, serum creatinine (with another parameter, such as diuresis) remains to date the reference parameter in the definition of AKI, as shown in Table 1 , where the most used classifications are reported.
It should be noted that a recent work of a Cambridge group 19 reinforces limits of using equations that do not take into account weight and height, especially in cancer patients. Janowitz and colleagues confront a gold standard measure of GFR, as (51Cr)-ethylenediaminetetraacetic acid (EDTA), obtained in a cohort of 2471 cancer patients, with seven different equations, finding that CKD-EPI body surface area (BSA)-adjusted formula has the highest accuracy, expressed by the lowest root-mean-square error (RMSE: 16.63 mL/min; 95% confidence interval (CI): 16.18-17.10 mL/min) versus gold standard and the least biased model (median residual: 0.54 mL/min; interquartile ranges (IQR): -10.18 to 9.16 mL/min). Notably, this model promises a greater accuracy in adjusting cisplatin dose according to renal function, thus reducing both undertreatment, in case of underestimated renal function, as toxicity, that occurs more frequently when GFR is overestimated in patients with CKD. To date, this equation needs anyway further investigations, given the low number of patients with GFR < 40 mL/min included in the study.
In a recent retrospective study 20 on more than 30,000 inpatients, significant differences in incidence of AKI were found according to the classification used. For example, when the K-DIGO criteria were used, the overall incidence of AKI was higher than that found with other classifications, as the cutoff threshold for AKI definition was lower with Kidney Disease Improving Global Outcome (KDIGO) criteria. CIAKI diagnosis accounted for 35% of overall AKI, and more than 50% of patients were classified as a stage 1 AKI. Many of these patients would not be classified as affected by AKI using the other classification criteria. It should be noted that the incidence of all-cause AKI was about 43% in stage IV CKD when patients were stratified by baseline GFR (K-DIGO criteria). The question of the criterion to use is of primary importance, at least to compare the literature data. However, from a clinical point of view, more effort should be made to improve differential diagnosis and follow up the outcome of CIAKI. Serum creatinine measurements should be repeated over time and integrated at least by anamnesis and urine analysis. An accurate differential diagnosis reduces the prevalence of CIAKI in inpatients, as suggested by the study of Nash et al., 21 who evaluated patients receiving either contrast-enhanced CT or endovascular procedures. CIAKI, defined as a creatinine increase of 0.5 mg/dL in 24-48 h after CM administration, occurred in 11% of patients, with an in-hospital mortality of 14%. However, only 4.2% of 4622 patients developed AKI after CT, with lower mortality rate in respect to those who underwent endovascular procedures.
Intra-arterial versus intravenous route of administration: defining a false battle
CM administration for interventional procedures, such as percutaneous transluminal angioplasty, is weighed by a higher CIAKI incidence, prolonged hospitalization, non-reversible deterioration of renal function, need for renal replacement therapy (RRT), and in-hospital mortality. [22] [23] [24] [25] [26] [27] [28] Indeed, AKI incidence in interventional procedures ranges from 20% to 70%, depending on AKI definition, the characteristics of the population, and the degree of urgency. For a long time, the arterial injection was supposed to play a nephrotoxic effect for the immediate delivery of CM to renal vessels. However, two considerations contradict this hypothesis: renal artery angiography and angioplasty are not burdened by the greatest incidence of AKI, and during coronary angiography, CM is drained by coronary veins and flows through pulmonary circulation before reaching the kidney. 22 Among the intra-arterial injection procedures, only those using femoral access are associated with a greater risk of AKI, due to a higher incidence of catheter-induced atheroembolic disease. 29 A large prospective study on inpatients 23 points out the impact of the comorbidities on the diagnosis and prognosis of CIAKI. The comorbidity index may represent the common substrate for the high incidence of AKI and negative outcome. The mortality (11.8%) and the incidence of major cardiovascular events (8.8%) were significantly higher in patients developing CIAKI (3%) then those observed in the remaining patients. Emergency/urgency procedures, creatinine clearance < 30 mL/min, body mass index (BMI), anemia, diabetes, heart failure, critical limb ischemia, and high contrast volume (volume/GFR ratio > 3) were significant predictors of CIAKI. Retrospective 30, 31 and prospective 32, 33 studies confirmed the opportunity of reducing the contrast volume below a threshold of 5 mL × Kg/serum creatinine or below the ratio (volume/ GFR) of 2. In order to provide a generally applicable cutoff, independently from the osmolality and molecular size of CM, Nyman et al. 34 suggested an iodine grams/GFR ratio of 1.2 as the maximum dose. In clinical practice, in a 70-kg patient with an MDRD-GFR of 35 mL/min/1.73 m 2 , a dose of 80 mL of LOCM 350 (that means 350 mg/ml) would ensure a prudential dose of 0.8 g/GFR and also a good radiological image quality.
There is no randomized study that assessed the CIAKI incidence and long-term outcome after endovascular procedures compared to contrast-enhanced CT. Recently, McDonald et al., 35 in a retrospective study including both inpatients and outpatients, compared two paired cohorts of patients who underwent Percutaneous transluminal coronary angioplasty (PTCA) or contrast-enhanced CT. The incidence of CIAKI was not different between the two procedures. Only 2.8% of the patients had stage 4 CKD (MDRD < 30 mL/min/1.73 m 2 ). Renal function recovery was more frequent when patients underwent PTCA (96%) compared to CT (89%), and also the need of RRT was more frequent (5.1% vs 1.8%) in patients receiving CT procedures. However, CT cohort presented a worse Charlson's score, received a greater amount of CM (average 120 vs 80 mL, given 70% of PTCA were diagnostic), and received a prophylactic hydration less frequently (46% vs 80%). Once again, population characteristics, dosage of CM, and prophylactic measures play an important role in the development of CIAKI. On the other hand, the frequent exclusion of critically ill patients (hemodynamic instability, severe CKD, intensive care unit patients, suspected pulmonary embolism, or aortic dissection) may explain the lower incidence of CIAKI in those studies that take into consideration only stable patients, outpatients, or selective populations. At present, the incidence, severity, and outcome of CIAKI in patients treated with urgent procedures, such as those with suspect pulmonary embolism 36 or admitted in intensive care units, 37 are comparable to that reported by cardiologists.
Contrast medium nephrotoxicity in the setting of CKD
A GFR < 45 mL/min was the stronger predictor of CIAKI in a large Korean registry study. 38 Prophylactic measures (mainly intravenous hydration and N-acetylcysteine [NAC]) reduce the Relative Risk (RR) from 14.17 to 9.96. There is less agreement on the role of CKD as a major risk factor in prospective studies. Five RCT [39] [40] [41] [42] [43] and four prospective observational studies, 38, [44] [45] [46] [47] including patients with CKD, showed an overall incidence of CIAKI ranging between 0% and 12%. Comparing the studies is not so easy for the heterogeneity of the outcome, follow-up, prophylactic protocols, framework (elective and urgent procedures), and CKD stratification. The two studies 43, 44 excluded patients with GFR < 30 mL/min. The two studies 39, 42 used serum creatinine threshold (>2.5 and 2.0 mg/dL), and one study 46 indicated MDRD < 30 mL/min/1.73 m 2 to define moderate-severe CKD (nearly 100 patients). Patients with specified stage IIIB CKD (GFR < 45 mL/min/1.73 m 2 ) were around 500. RCT had a maximum follow-up of 35 days, with no fatal events or need for RRT in the entire population (1292 patients). Advanced kidney failure was not documented as a major relative risk factor. However, in a recent and more large study, 43 no difference in CIAKI incidence (2.6%-2.7%) according to prophylaxis measures was found, and hydration did not influence the primary outcome in patients with GFR < 45 mL/min/1.73 m 2 . However, the small sample size of the subgroup resulted in wide CIs, with upper levels exceeding the non-inferiority margin, as the same authors reported. Thus, these data are not conclusive, and prospective studies with adequate statistical power are needed to assess the risk of CIAKI without prophylactic measure in patients with moderate-advanced CKD.
In 2010, Kim et al. 46 published an observational work that may provide some information about CIAKI onset and renal outcome. In stage 4 and 5 CKD subgroups, the incidence of CIAKI (defined as a 25% increase of serum creatinine compared to baseline level) was 6.9%, about three times higher than that observed in the overall population. About 90% of the study population had stage 3 CKD, and no CIAKI was observed if GFR was >45 mL/min. All patients were treated with normal saline (NS) and NAC before and after contrast medium administration. No fatal events occurred, but 3 out of 13 patients with CIAKI required RRT within 4 months, and 4 of the remaining 10 started RRT within 14 months. In the subgroup with GFR < 30 m/min, CIAKI resulted as a significant risk factor for RRT. Nine out of 13 patients who developed CIAKI were diabetics. In diabetic nephropathy, a median decline of GFR of 4.4-5.2 mL/min/1.73 m 2 per year is expected, depending on blood pressure control, proteinuria, and medical treatment, 48 a rate clearly lower than that observed in Kim's population with a baseline GFR > 20 mL/min, suggesting a possible direct effect of CIAKI on long-term renal function deterioration in this subgroup.
Prophylactic measures to prevent CIAKI
A review on the effectiveness of preventive measures was recently published by the Agency for Healthcare Research and Quality. 49 The authors selected 163 RCTs and 23 prospective observational studies with both intra-arterial and intravenous CM administration, and compared the effectiveness of NS, half saline (NS1/2), oral NAC, IV sodium bicarbonate, statins, or ascorbic acid in the prevention of renal damage. Other treatments (such as adenosine or dopamine) showed an insufficient strength of evidence to prove their effectiveness. A clinically important and statistically significant reduction in CIAKI was observed when NAC was compared to the NS of patients receiving LOCM, and the strength of evidence was moderated (pooled risk ratio: 0.69; 95% CI: 0.58-0.84). NAC is a high bioavailable component of glutathione, an electron acceptor widely involved in organic peroxides and ROS neutralization. Given the direct cytotoxic role of ROS generation as second step of hypoxic damage in CIAKI pathogenesis, the administration of NAC seems to be a reasonable protective strategy. According to the European Society of Urogenital Radiology (ESUR) Guidelines on CM, hydration with NS or sodium bicarbonate-but not NAC-are recommended as preventive measures for CIAKI in patients at risk. 50 The American College of Radiology has recently published its Albumine/Creatinine Ratio (ACR) manual on CM, showing the same opinion about NAC, because of different and conflicting results in several meta-analyses. 51 Sodium bicarbonate 49 was more effective than saline in preventing CIAKI only when LOCM was used (pooled risk ratio: 0.65; 95% CI: 0.33-1.25; low strength of evidence). The remaining interventions share small clinical benefits and showed low strength of evidence. None of the studies examined in the ACR manual were designed to compare volume expansion to no hydration. At the end of the article, the authors wish for larger studies in patients at high risk for CIAKI, as diabetics and CKD patients, since it is difficult to prove the effect of a preventive strategy in subjects with low risk of CIAKI. Waiting for these future studies, the choice between NS and sodium bicarbonate solutions should be guided by the patients' acid-base status.
Hemodialysis 49 did not reduce the risk of CIAKI and may be harmful compared to saline (pooled risk ratio: 1.50; 95% CI: 0.56-4.04, low strength of evidence). From a theoretical point of view, hemodialysis could be an effective strategy to prevent CIN, given the high removal rate of CM with a 4-h session, due to the low molecular weight (700-1550 Da), low distribution volume, minimal plasmatic protein binding, and a single pool kinetics of CM. Actually, kidney hypoxic damage began within minutes from CM injection, while a dialysis session is not so fast in removing it. Furthermore, the interval between CM injection and dialysis cannot be less than 60-90 min for obvious technical and organizational reasons.
Continuous hemofiltration techniques have a lower removal rate of CM compared to standard hemodialysis. The attempts to remove CM starting hemofiltration treatment before CM administration failed to demonstrate an advantage in CIAKI prevention and outcomes. 52 Conversely, central venous catheter placement, anticoagulation requirement, and unnecessary mechanical dehydration expose the patients to serious adverse events (vessel lesions, thrombosis, bleedings, severe hypotension). As for the decrease in serum creatinine as a marker of prevention of CIAKI, a clear and heavy confounding factor is the fact that dialysis treatment reduces serum creatinine level, thus invalidating every positive creatinine-based result.
The radiologist's request to perform dialysis session in patients' chronic RRT after procedures with CM infusion is not justified except for patients with a significant residual renal function.
Loop diuretics increasing tubular flow rate and reducing renal medullar oxygen consumption through basal Na-K-Cl cotransporter inhibition have the physiological assumption to prevent CM renal damage. However, these potential benefits may be blunted by the intravascular volume depletion that activates the RAAS and induces renal hypoxia, worsening as a consequence the nephrotoxic effect of CM. 53 Two recent studies 54, 55 suggest that loop diuretics reduce CIAKI incidence, if the extracellular volume is preserved through an adequate intravenous hydration to offset fluid losses, even in patients with CKD and left ventricular dysfunction, more prone to pulmonary edema. In clinical practice, a clinical and vital sign-guided assessment of volume repletion status is recommended before using diuretic therapy.
No data are available about protective or deleterious effects of Angiotenin converting enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs) in patients undergoing a contrast-enhanced CT. Data from interventional procedures in patients with coronary disease, also showing conflicting results, 56, 57 should not be taken as a paradigm. Theoretical favorable effects by means of Angiotensin converting enzyme 2 (ACE2)-mediated vasodilation and Angiotensin II (AT2) receptor mediated Nitric oxyde sinthase (NOS) upregulation may be counterbalanced by renal hypo-perfusion and reduction of glomerular filtration pressure, leading to detrimental effect on CIAKI occurrence in these patients. In clinical practice, if we cannot be sure of patient's hydration status, it could be reasonable to temporarily discontinue these classes of drugs, as well as other class of antihypertensive drugs.
Avoiding non-steroidal anti-inflammatory drugs (NSAID) in pre-and post-procedural days is mandatory to prevent NOS inhibitions that may clearly worsen the hypoxic renal damage induced by CM.
Dealing with a diabetic patient perceived at high CIAKI risk, it is reasonable to discontinue metformin in order to avoid lactic acidosis in the case of AKI. Although the prescription of substitute oral antidiabetic drug, or even insulin, is crucial-in an attempt to ward off a volume depletion caused by osmotic diuresis in the setting of an uncontrolled hyperglycemia. Table 2 summerises prophylactic measures according to current literature. Table 2 . Advice before performing examinations or procedures with CM in cancer patients.
Use eGFR (MDRD, CKD-EPI) or measure creatinine clearance to evaluate kidney function at baseline Prepare patients with IV hydration (3 mL/kg/h for at least 4 h, in absence of congestive signs or symptoms) if affected by CKD stage IIIB or more, solitary kidney, diabetic nephropathy, or high comorbidity index Discontinue diuretic treatments the day before to ensure adequate intravascular repletion Measure central venous pressure in critically ill and Chronic Heart Failure patients to ensure an optimal match between IV hydration rate and forced diuresis when diuretic treatment is indicated Avoid NSAID and other nephrotoxic drugs during the week before CM infusion Measure serum creatinine levels 5 days after CM infusion and ask a nephrologist's consult if serum creatinine increases and/or a differential diagnosis is needed CKD: chronic kidney disease; IV: intravenous; CM: contrast media; NSAID: Non-steroidal anti-inflammatory drugs.
CIAKI in solitary kidney and cancer
A unique retrospective and rigorous investigation about CIAKI risk in solitary kidney patients appeared in 2015, signed by McDonald et al. 58 Propensity score matching failed to document a greater incidence of CIAKI (4.1% vs 4.2%), greater need for Renal Replacement Therapy (RRT), or mortality related to kidney failure in solitary kidney group (247 patients). Patients with solitary kidney underwent nephrectomy for cancer disease. Baseline GFR was the main risk factor for CIAKI. The recovery of renal function after nephrectomy in kidney donors reaches 70%-80% of prenephrectomy GFR due to compensatory renal hypertrophy. 59 On the other hand, CM exams are often prescribed to patients with metastatic or high-grade cancer during the early period after nephrectomy, when hypertrophy has not developed yet.
Waiting for prospective studies, intravenous hydration, and/ or NAC administration seems to be the safest strategy, especially when patients undergo active cancer therapy.
A recent population-based cohort study 60 on 7100 stage 3 CKD patients in Taiwan (medium follow-up of more than 4 years) pointed the augmented risk of developing End Stage Renal Disease (ESRD) after multiple CM examinations. They used matched cohorts to reduce bias for confounding effects of other known risk factors for ESRD, as diabetes or chronic heart failure. The Hazard Ratio (HR) was 12.08 (95% CI: 7.39-19.7), if CM was infused more than twice a year compared to a control matched cohort that underwent CT scan without CM. In the same study, a single annual exposure to CM was not associated with an increased risk of ESRD in CKD patients (Adjusted Hazard Ratio (AHR): 0.91; 95% CI: 0.66-1.26).
Cancer patients share both a high frequency of CM examinations and a high incidence of CKD. 3 The retrospective study of Hong et al. 61 in 820 cancer patients with serum creatinine < 1.5 mg/dL (about 8% with MDRD < 60 mL/ min/1.73 m 2 ) shows the role of the preventive measures in reducing the risk of kidney deterioration in cancer patients. The CIAKI (increase of serum creatinine >0.5 mg/dL or >25% above baseline, within 72 h of the CM infusion) incidence was 8% in absence of prophylactic measures. The mean age of the population was about 60 years. Most patients were affected by solid neoplasms, 50% were on cancer treatment, and 20% were diabetics. Multivariate regression analyses identified serial CT scans (within 48 h), signs of intravascular volume depletion, Blood Urea Nitrogen (BUN)/serum creatinine ratio > 20, hypotension, liver cirrhosis, and peritoneal carcinomatosis as the risk factors for CIAKI. Mortality was higher (10.6% vs 2.3%) in those subjects who experienced CIAKI, but only one death (due to multiple organ failure secondary to esophageal perforation) was related to severe renal injury with need of RRT.
Retrospective 62 and prospective 63 data on cancer patients with normal or mild decreased renal function, hospitalized in both intensive and non-intensive units, mainly in active cancer treatment, reported an incidence of CIAKI of up to 27.9%, depending on the marker used (cystatin C, absolute or percent increase of serum creatinine). However, the CIAKI incidence was comparable to the control group receiving CT without CM, 62 and CIAKI was not associated with renal outcomes, even in the absence of preventive measures. 63 These findings underline how cancer patients are prone to AKI, regardless of its cause, and that CIAKI occurrence in the absence of a moderate-severe kidney failure does not induce a permanent kidney damage. Conversely, Cheruvu et al. 64 retrospectively found that irreversible CIAKI incidence (4.8%) in patients partly with stage 3 CKD was significantly higher than in patients with normal baseline renal function. However, no patient required RRT, and the only preventive measure taken was the advice to increase oral fluid intake.
Focusing on elderly cancer patients, Park and Lee 65 evaluated an in-hospital cohort of patients selected by age (>65 years) and serum creatinine level (<1.5 mg/dL) who underwent a CM examination. CIAKI incidence (increase of serum creatinine > 0.5 mg/dL) was 14.4% and correlated with baseline GFR. Comparing three different computed-based formulas for GFR estimation, they found that the highest RR for CIAKI was detected by CKD-EPI formula, which was also able to predict the risk for in-hospital mortality. Intriguingly, renal function determination by Cockroft-Gault formula, which takes into account not only age and sex but also the weight, showed lower statistical power. This information is not surprising in elderly cancer patients who are characterized by depleted muscle masses and confirm the risk of underestimating renal function using only serum creatinine as a marker. In in-hospital subjects, the measurement of creatinine clearance, taking advantage of a more accurate nursecontrolled 24 h urine collection, could be more informative.
In the prospective study of Balemans et al. 47 on 747 patients with a GFR < 60 mL/min/1.73 m 2 , the incidence of CIAKI (increase of serum creatinine > 25%) was 2.4%, and 70% of patients who experienced CIAKI were cancer patients. The low incidence of CIAKI despite the presence of CKD was explained by the use of prophylactic hydration in about 54% of patients. Repeated CM examinations, BMI, and heart failure (but not neoplasia) were identified as risk factors for CIAKI.
The effect of chemotherapy on the risk of developing CIAKI was investigated by Turkish researchers in a prospective cohort of 90 inpatients with cancer and GFR > 50 mL/ min/1.73 m 2 . 18 No prophylactic measure was taken before CM infusion. CIAKI was more frequent in patients who had an interval less than 45 days between CM and chemotherapy. CIAKI developed four to five times more frequently in those patients who received recent chemotherapy. The combination of bevacizumab and irinotecan was considered an additional risk factor for CIAKI. A possible explanation was the pro-apoptotic effects on endothelial renal cells of bevacizumab due to its effect on Vascular Endotelial Growth Factor A (VEGF-A), with the subsequent reduction of NO synthesis and magnification of CM renal hypoxic damage, in the presence of dehydration status resulting from gastrointestinal losses due to irinotecan administration. The incidence of AKI may raise by 2.5 times when CM examinations are performed in the first 7 days after a cisplatin cycle, despite an optimal hydration scheme and a normal baseline renal function. 17 Indeed, CM and cisplatin have a common damage pathway through ROS generation and renal vasoconstriction. Table 3 underlines the lack of data about oncological drugs as a risk factor for CIAKI. 
Conclusion
CKD and volume depletion are the major risk factors for the augmented risk of CIAKI. There are simple and economic tools to identify subjects at high risk of kidney damage by CM: the creatinine-based and cystatin-C-based formulas to estimate the GFR, the evaluation of the pharmacological history, the concomitant medications as well as the comorbidity index. The risk of CIAKI may be minimized by the administration of a CM dose adjusted for GFR and prophylactic use of intravenous hydration. In cancer patients, the need for repeated radiologic examinations and the associated chemotherapy make these concerns even more cogent. Knowledge of population at risk and the use of prophylactic measures may assure the possibility to safely provide CM procedures to cancer and CKD patients as well. A multidisciplinary approach that involves oncologists, radiologists, and nephrologists may convert a ghost into a challenge.
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